HealthCDC

Explainer

Updated

Who should get the COVID vaccine?

Key facts

For children 6 months through 17 years who are not moderately or severely immunocompromised, the CDC says the vaccine is a shared decision with a health care provider.

The Centers for Disease Control and Prevention recommends a 2026-2027 COVID-19 vaccine for all adults 18 and older and for all children 6 months through 17 years who are moderately or severely immunocompromised. For all other children in that age range, the CDC recommends a COVID-19 vaccine through shared clinical decision-making, a decision made between a health care provider and the patient or parent. This page reports what the CDC and the FDA state and is not medical advice.

The CDC recommendation, group by group

As listed in the CDC's clinical considerations and immunocompromised guidance, both updated September 23, 2026, and its vaccine benefits page, updated October 8, 2026:

GroupWhat the CDC recommends
Adults 18 to 64A 2026-2027 vaccine
Adults 65 and olderA 2026-2027 vaccine, and a second dose 6 months after the first
Moderately or severely immunocompromised, 6 months and older2 doses of 2026-2027 vaccine spaced 6 months apart for those who completed an initial series; 3 or 4 doses for those never vaccinated
Children 6 months through 17 years, not immunocompromisedShared clinical decision-making

The CDC's benefits page gives the reason for the second dose: adults 65 and older and people with a weakened immune system have a higher risk for severe COVID-19. The same page says a COVID-19 vaccine during pregnancy helps protect the mother and helps protect the baby before the baby becomes eligible for vaccination at 6 months old.

The CDC's clinical considerations add that all patients should discuss the benefits and risks of COVID-19 vaccination with their health care providers to make informed and personalized decisions.

What shared clinical decision-making means for children

The CDC's child schedule notes say these vaccinations are individually based and informed by a decision process between the provider and the patient or parent or guardian. Where a parent wants a child vaccinated, the notes say children 6 months and older may receive a COVID-19 vaccine, informed by the provider's clinical judgment and personal preference and circumstances. The same notes list 18-year-olds who are not moderately or severely immunocompromised under routine vaccination.

The CDC said in an October 6, 2025 release that individual-based decision-making, which its schedules call shared clinical decision-making, allows coverage through all payment mechanisms, as routine recommendations do, including Medicare, Medicaid, the Children's Health Insurance Program, the Vaccines for Children Program and insurance plans regulated by the Affordable Care Act.

People who are immunocompromised

COVID-19 vaccination is recommended for people 6 months and older who are moderately or severely immunocompromised, the CDC's immunocompromised guidance says, on a schedule set by age and vaccination history. The cases a reader meets next:

  • No paperwork needed. People can self-attest to being moderately or severely immunocompromised, and the CDC says vaccinators should not deny vaccination for lack of documentation.
  • Never vaccinated. An unvaccinated person 12 or older gets 3 or 4 doses of the 2026-2027 vaccine, depending on the brand: an initial series followed by 1 dose 6 months later.
  • Already vaccinated. Someone who completed the initial series before the 2026-2027 vaccines gets 2 doses of the new vaccine spaced 6 months apart.
  • Transplants and CAR-T. Recipients of a hematopoietic cell transplant or CAR-T-cell therapy who got a COVID-19 vaccine before or during treatment should be revaccinated, starting at least 3 months after the transplant or therapy.
  • Which conditions count. The CDC's list includes active cancer treatment, an organ or islet transplant with immunosuppressive therapy, moderate or severe primary immunodeficiency, advanced or untreated HIV, and high-dose corticosteroids of 20 mg or more of prednisone or the equivalent a day for 2 or more weeks.

Which vaccines the FDA has approved, and for whom

The FDA advised manufacturers that COVID-19 vaccines for use beginning in fall 2026 should be a monovalent vaccine aimed at the JN.1-lineage XFG variant, after its advisory committee met on May 28, 2026. Each FDA product page lists an approval letter dated August 27, 2026. The approved ages:

VaccineMaker on FDA pageFDA-approved for
ComirnatyBioNTech65 and older, or 5 through 64 with a high-risk condition
SpikevaxModerna65 and older, or 6 months through 64 with a high-risk condition
MnexspikeModerna65 and older, or 12 through 64 with a high-risk condition
NuvaxovidSanofi65 and older, or 12 through 64 with a high-risk condition

In each case the FDA's wording is at least one underlying condition that puts the person at high risk for severe outcomes from COVID-19. For people under 65, the FDA approvals cover only those with such a condition, while the CDC recommendation covers all adults 18 and older. The CDC says its clinical considerations mark where a recommendation describes use outside the FDA-approved indication as off-label.

The edges a reader meets next:

  • Youngest children. The Pfizer-BioNTech vaccine is no longer authorized for children 6 months through 4 years, and Spikevax is the only FDA-approved COVID-19 vaccine available for that age group, the CDC says.
  • Extra doses in young children. FDA approval is limited to two doses for children 6 to 23 months and one dose for children 2 to 4 years, so the CDC's immunocompromised guidance labels its recommendation for more doses in those ages off-label.
  • Emergency use ending. On June 29, 2026, the HHS Secretary determined that circumstances no longer justify emergency use authorizations for COVID-19 drugs and biological products, and the declaration will be terminated effective June 29, 2027, the FDA says.

What changed and when

  • May 29, 2025. The CDC's child schedule addendum says that as of this date the schedule incorporates the HHS directive on COVID-19 vaccine recommendations, with changes for pregnant women and for children 6 months through 17 years who are not moderately or severely immunocompromised. The adult addendum notes the change for pregnant women.
  • July 2, 2025. The CDC's adult schedule notes, dated that day, name the 2024 to 2025 vaccines and give adults 65 and older a second dose 6 months after the first.
  • October 6, 2025. The CDC updated its adult and child schedules to apply individual-based decision-making to COVID-19 vaccination, adopting recommendations of its Advisory Committee on Immunization Practices.
  • January 5, 2026. Acting CDC Director Jim O'Neill signed a decision memorandum accepting recommendations from an assessment of U.S. childhood immunization practices, as the CDC moved to update the childhood immunization schedule.
  • May 28, 2026. The FDA's advisory committee recommended the XFG variant for the 2026-2027 vaccines.
  • September 23, 2026. The CDC updated its clinical considerations for the 2026-2027 vaccines and said: "Because of legal uncertainties and inquiries, the CDC states the recommendations for COVID-19 vaccination from the July 2025 immunization schedule remain in effect for the 2026-2027 respiratory illness season."

Flu vaccine guidance is on who should get a flu shot, and RSV vaccine guidance is on who can get the RSV vaccine.

COVID-19 right now

Current variants are covered on the new COVID variant. For the national trend, see whether COVID cases are rising, and for what the illness looks like, the symptoms of COVID.

Have another question?